High doses of saw palmetto don't impact serum PSA

February 8, 2013
High doses of saw palmetto don't impact serum PSA
Compared with placebo, saw palmetto, even at a dose as high as 960 mg, does not affect serum prostate-specific antigen levels in men with lower urinary tract symptoms, according to research published in the February issue of The Journal of Urology.

(HealthDay)—Compared with placebo, saw palmetto, even at a dose as high as 960 mg, does not affect serum prostate-specific antigen (PSA) levels in men with lower urinary tract symptoms, according to research published in the February issue of The Journal of Urology.

Gerald L. Andriole, M.D., of the Washington University School of Medicine in St. Louis, and colleagues conducted the randomized, placebo-controlled for Urologic Symptoms trial involving 369 men over the age of 45 with lower . Participants were randomized to placebo or escalating doses of saw palmetto (320, 640, and 960 mg for 24 weeks each). Serum PSA levels were assessed at baseline, 24, 48, and 72 weeks.

The researchers found that, during the study, similar changes in PSA were observed, with a mean change of 0.16 ± 1.08 ng/mL and 0.23 ± 0.83 ng/mL in the placebo and saw palmetto groups, respectively (P = 0.50). When the groups were stratified by baseline PSA there was no differential effect on serum PSA between the treatment arms.

"The results of this study are clinically relevant to men's health. While convincing data have established the lack of of saw palmetto in alleviating , many men continue to take this medication," the authors write. "By definitively establishing the lack of an effect on PSA by saw palmetto, even at supra-standard doses, our study confirms that clinicians need not adjust serum PSA in men taking this herbal supplement who opt to undergo such testing for prostate cancer early detection."

Explore further: Popular supplement - saw palmetto extract - has no effect on prostate health: study

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

Savior of T-cells may be enemy of liver immune cells

April 24, 2017

Researchers at Houston Methodist demonstrated that a surface protein called OX40, responsible for keeping one type of immune system cell alive, can trigger the death of liver immune cells, in turn starting a chain reaction ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.